EUVIMEDEUVIMED entdecken
Crossref

Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation

Elena Orlova-Morozova, Dmitry Kireev, Alina Kirichenko, Vyacheslav Bobkov, Anastasiya Antonova iD, Rafael Yapparov iD, Marina Bobkova iD

HIV Medicine · 2025

DOI: 10.1111/hiv.70073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Elena Orlova-Morozova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Emtricitabine, Tenofovir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aimed to evaluate the effectiveness of bictegravir (BIC)‐based antiretroviral therapy (ART) against HIV‐1 sub‐subtype A6 viruses carrying the L74I polymorphic mutation in integrase.

Methods

A total of 100 ART‐naive people living with HIV from the Moscow Regional AIDS Center were enrolled between May and July 2023. HIV‐1 subtypes and baseline drug resistance mutations were analysed prior to treatment initiation. All patients began a first‐line ART regimen and were followed for 40–48 weeks, at which point viral load (VL) was assessed.

Results

HIV‐1 sub‐subtype A6 was identified in 78% of people living with HIV; among these, the L74I mutation was present in 97.3%. Of those carrying the mutation, only one patient experienced treatment failure, attributed to very low adherence.

Conclusions

The BIC/FTC/TAF regimen is fully effective in treatment‐naive people living with HIV infected with HIV‐1 sub‐subtype A6 harbouring the L74I integrase mutation. These findings support the continued use of second‐generation integrase strand transfer inhibitor (INSTI)‐based regimens for individuals with this HIV‐1 subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1EmtricitabineTenofovirAnti-HIV AgentsHeterocyclic Compounds, 4 or More RingsHumansMaleFemaleAdultMutationMiddle AgedViral LoadDrug Resistance, ViralPyridonesAlanineTreatment OutcomePiperazinesHIV IntegraseAmidesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Bictegravir/Emtricitabine/Tenofovir alafenamideHIV‐1L74I mutationintegrasepreexisting resistancesub‐subtype A6treatment efficacy

Substanzen

EmtricitabineTenofovirAnti-HIV AgentsbictegravirPyridonesHeterocyclic Compounds, 4 or More RingsAlaninePiperazinesHIV Integrasetenofovir alafenamide

Autor:innen und Institutionen

  • Moscow Regional AIDS Center, Moscow Region, Kotelniki, Russia.
  • Central Research Institute of Epidemiology, Moscow, Russia.
  • Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.
  • Gamaleya National Research Center of Epidemiology and Microbiology, Moscow, Russia.

ORCID-Profile: Anastasiya Antonova, Rafael Yapparov, Marina Bobkova

Förderung

  • Russian Science Foundation

Zitieren

APA

Orlova-Morozova, E., Kireev, D., Kirichenko, A., Bobkov, V., Antonova, A., Yapparov, R., & Bobkova, M. (2025). Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation. HIV Medicine. https://doi.org/10.1111/hiv.70073

Vancouver

Orlova-Morozova E, Kireev D, Kirichenko A, Bobkov V, Antonova A, Yapparov R, et al. Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation. HIV Medicine. 2025. doi:10.1111/hiv.70073

BibTeX
@article{OrlovaMorozova2025,
  author = {Orlova-Morozova, Elena and Kireev, Dmitry and Kirichenko, Alina and Bobkov, Vyacheslav and Antonova, Anastasiya and Yapparov, Rafael and Bobkova, Marina},
  title = {Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV ‐1 sub‐subtype A6 harbouring the L74I mutation},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70073}
}
Kostenlos starten →